Speclipse

Seongnam-si, South Korea Founded: 2015 • Age: 11 yrs Acquired By Cellreturn
Molecular spectroscopy systems for early skin cancer detection are provided.
Request Access

About Speclipse

Speclipse is a company based in Seongnam-si (South Korea) founded in 2015 was acquired by Cellreturn in November 2019.. Speclipse has raised $10.55 million across 2 funding rounds from investors including Shinhan Financial Group, Mico and MiCoBioMed. Speclipse offers products and services including Spectra-Scope®, Pico-K, and Bellus-Q. Speclipse operates in a competitive market with competitors including Bruker, Metrohm, Impedimed, Rigaku and Anvajo, among others.

  • Headquarter Seongnam-si, South Korea
  • Sectors
    Healthcare
    Technology
  • Phone
    *********
  • Website
    *********
  • Legal Name Speclipse, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Technology → Quantum & Emerging Technologies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $10.55 M (USD)

    in 2 rounds

  • Latest Funding Round
    $8 M (USD), Series A

    Aug 19, 2021

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Cellreturn

    (Nov 05, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Speclipse

Speclipse offers a comprehensive portfolio of products and services, including Spectra-Scope®, Pico-K, and Bellus-Q. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Portable tool for detecting skin cancer via laser and AI analysis.

Picosecond laser for effective skin lesion removal and therapy.

Advanced laser device for precise dermatological treatments.

People of Speclipse
Headcount 1-10
Employee Profiles 2
Employee Profiles
People
Sung Hyun Pyun
Founder and CEO
People
Boncheol Goo
Chief Marketing Officer

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Speclipse

Speclipse has successfully raised a total of $10.55M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $8 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $8.0M
  • First Round

    (18 Nov 2016)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2021 Amount Series A - Speclipse Valuation Signite Partners
Nov, 2016 Amount Seed - Speclipse Valuation Mega Investment , InterVest
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Speclipse

Speclipse has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Shinhan Financial Group, Mico and MiCoBioMed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
-
Founded Year Domain Location
Financial group
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Speclipse

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Speclipse

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Speclipse Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Speclipse

Speclipse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bruker, Metrohm, Impedimed, Rigaku and Anvajo, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Diversified research instrument systems are manufactured and supplied.
domain founded_year HQ Location
Instruments for chemical analysis are developed and manufactured.
domain founded_year HQ Location
Technologies for non-invasive fluid status assessment and monitoring are developed.
domain founded_year HQ Location
XRD, XRF, SAXS, Raman, metrology, and crystallography solutions are provided.
domain founded_year HQ Location
Point-of-care solutions for laboratory diagnostics are provided by Anvajo.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Speclipse

Speclipse Raises $7.7M in Funding
Finsmes4 years ago

Frequently Asked Questions about Speclipse

When was Speclipse founded?

Speclipse was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Speclipse located?

Speclipse is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.

Is Speclipse a funded company?

Speclipse is a funded company, having raised a total of $10.55M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.55M, raised on Nov 18, 2016.

What does Speclipse do?

Speclipse was founded in 2015 and is based in Seongnam-si, South Korea. Molecular spectroscopy systems are offered for early-stage skin cancer detection within the medical diagnostics sector. A non-invasive tool utilizing laser spectroscopy and statistical algorithms has been developed to analyze tissue chemical composition in vivo. Operations focus on in-vivo laser technology for diagnostic applications in healthcare.

Who are the top competitors of Speclipse?

Speclipse's top competitors include Bruker, Metrohm and Impedimed.

What products or services does Speclipse offer?

Speclipse offers Spectra-Scope®, Pico-K, and Bellus-Q.

Who are Speclipse's investors?

Speclipse has 9 investors. Key investors include Shinhan Financial Group, Mico, MiCoBioMed, Mega Investment, and Signite Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available